急性心筋梗塞の後のプラズマ脂質に対する長期のプラクトロル療法の効果
Lancet (London, England)
|January 4, 1975
まとめ
長期のプラクトロール治療は,12ヶ月間にわたって急性心筋梗塞から回復している患者の血脂質レベルを有意に変化させませんでした.
科学分野:
- 心臓病学 心臓病学
- 薬理学 薬理学とは
背景:
- 急性心筋梗塞 (AMI) は,心血管疾患による死亡の主な原因です.
- 脂質管理は,AMI後の患者のケアにおいて極めて重要です.
- ベータブロッカーが脂質プロファイルに与える長期的な影響については,さらなる調査が必要である.
研究 の 目的:
- プラズマ脂質濃度に対する長期のプラクトロール治療の影響を評価する.
- 急性心筋梗塞後の脂質プロフィールの管理におけるプラクトロロルの安全性と有効性を評価する.
主な方法:
- 12ヶ月間,ダブルブラインドでコントロールされた試験が行われました.
- 急性心筋梗塞を経験した20人の患者が登録されました.
- 試験期間中,血脂濃度がモニタリングされました.
主要な成果:
- 長期のプラクトロール治療は,血脂質濃度に有意な効果を示さなかった.
- 試験中に脂質代謝に有害な影響は見られなかった.
結論:
- プラクトロール治療は,心筋梗塞後の患者の血脂質濃度に悪影響を及ぼさないようです.
- この患者集団におけるプラクトロロルのより広範な心血管上の利点または制限を調査するために,さらなる研究が必要になる可能性があります.
さらに関連する動画
05:26Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
Published on: May 28, 2019
14:35Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
Published on: April 17, 2021
関連する概念動画
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Coronary Artery Disease V: Interprofessional Care
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Acute Coronary Syndrome IV: Interprofessional Care
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Angina IV: Management
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
